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Spermine and spermidine are non-specific inhibitors of in vitro
hematopoiesis. The polyamine spermine has been reported to be the
inhibitor of in vitro erythropoiesis present in uremic serum. We have
employed a panel of hematopoietic colony—forming assays to evaluate
the specificity of the inhibitory activity. Spermine and its precursor
spermidine when added to culture inhibited mouse and human erythroid
(CFU-E and BFU-E), granulocyte—macrophage, and megakaryocyte
colony growth in a non-specific, dose—dependent fashion. Erythroid
and non-erythroid colony growth were equally sensitive to spermine—
and spermidine—induced inhibition. Increasing concentrations in culture
of erythropoietin and mitogen—stimulated leukocyte—conditioned me-
dium, a source of colony—stimulating activity, failed to overcome the in
vitro inhibition. Although anemia is characteristic of chronic renal
failure (CRF), leukopenia and thrombocytopenia are not. Therefore, we
conclude that the non-specific inhibitory activity of spermine and
spermidine, as defined by in vitro colony assays, is either of no
pathophysiologic significance in the anemia of CRF, or else there are
unrecognized repair mechanisms in vivo which maintain granulopoiesis
and thrombopoiesis at normal levels.
Patients with the anemia of chronic renal failure (CRF) fail to
display an appropriate compensatory erythropoietic response
[1]. It is now widely accepted that the reduced production of
erythropoietin (Ep) is a major determinant of the impaired
marrow response [2, 3]. In addition, it has been proposed that
retained inhibitors of erythropoiesis may contribute to the
anemia of CRF [4). Two sets of observations provide indirect
support for a pathogenetic role of uremic inhibitors. First, the
institution of chronic dialysis therapy frequently is associated
with improvement in hemoglobin concentration without ef-
fecting any increase in serum Ep levels [5, 6]. Second, serum
Ep levels in these patients, although inappropriately low for the
degree of anemia, are often above the levels in normal non-
anemic individuals [4, 6—8].
A number of investigators have attempted to characterize the
putative inhibitors by examining the effect of whole or fraction-
ated uremic sera on in vitro erythropoiesis. Most workers have
observed that uretnic serum, compared to normal serum, sig-
nificantly inhibits hemoglobin synthesis or erythroid colony
growth from human or murine marrow cells [8—12]. Likewise,
several candidate uremic toxins have been identified [10, 131.
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Radtke et al [10] have reported that most, if not all, of the
erythropoietic inhibitory activity in uremic serum is associated
with the polyamine spermine.
While anemia is a common finding in CRF patients, leukope-
nia and thrombocytopenia are rarely seen. Accordingly, if
uremic inhibitors identified by in vitro assays are of pathophys-
iologic significance, they might exhibit erythroid lineage speci-
ficity or, at least, inhibit in vitro erythropoiesis to a greater
degree than granulopoiesis or megakaryocytopoiesis. No stud-
ies to date have examined concurrently non-erythroid colony
growth from the same target cells to determine the specificity of
potential inhibitors of erythropoiesis [8—13].
Recently, we demonstrated that uremic serum inhibits mu-
rine granulocyte—macrophage and megakaryocyte colony
growth to the same extent as erythroid colony growth [14]. We
now show that spermine and spermidine also non-specifically
inhibit human and murine erythropoiesis, granulopoiesis, and
megakaryocytopoiesis in vitro. Moreover, this inhibition was
not overcome by increasing concentrations of Ep or a source of




Marrow cells were obtained from six to eight—week—old male
C57BL/6 mice (Jackson Laboratories, Bar Harbor, Maine,
lA) by flushing the femoral shafts with alpha medium (Gibco,
Grand Island, New York, USA) supplemented with 5% heat—
inactivated fetal calf serum (FCS; M.A. Bioproducts, Walkers-
ville, Maryland, USA).
Marrow cells, human
Marrow cells were obtained from normal adult volunteers
with informed consent and the approval of our institution's
Human Subjects Review Committee. Cells were aspirated from
the posterior iliac crest into plastic syringes containing 250 units
of preservative—free heparin (O'Neal, Jones, & Feldman, St.
Louis, Missouri, USA). Low—density mononuclear cells were
isolated by density centrifugation on Ficoll—diatrizoate (1.077
g/ml; LSM®, Litton Bionetics, Kensington, Maryland, USA) as
previously described [15].
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Mouse colony—forming assays
For most experiments, erythroid colonies were grown in
methyiceilulose culture by a modification of the technique of
Iscove, Sieber and Winterhalter [16]. In brief, marrow cells
were cultured at a concentration of 105/mi in alpha medium
supplemented with 30% FCS, 1% deionized bovine serum
albumin (Sigma, St. Louis, Missouri, USA), iO M /3-mercap-
toethanol, 10 mivi L-glutamine, 100 U/mi penicillin, 100 tg/ml
streptomycin, 1 unit/mi human urinary Ep, and 0.5% phyto-
hemagglutinin—stimulated LBRM-33 cell—conditioned medium
(PHA-LBRM) [17] and made semi-solid with 1% methylcellu-
lose (Eastman Kodak, Rochester, New York, USA). One ml
volumes were dispensed into 35 mm piastic tissue cuiture dishes
(Lux®, Miies Laboratories, Naperville, Illinois, USA) and
cultured at 37°C in 5% CO2 in air. Erythroid colonies (from
CFU-E) and bursts (from BFU-E) were enumerated after two
and seven days of culture, respectively, using an inverted
microscope. Aggregates of eight or more hemoglobinized cells
were scored as CFU-E-derived colonies. Erythroid bursts were
identified as colonies of at least 200 hemoglobinized cells or as
aggregates of two or more hemoglobininzed sub-colonies. In
several experiments, cultures were performed in plasma clot
and erythroid colonies identified by 3,3'-dirnethoxybenzidine
staining as previously described [181.
Granulocyte—macrophage and megakaryocyte colonies were
grown in methylcellulose by a modification of the method of
Burstein et al [19]. Marrow cells were cultured at a concentra-
tion of io cells/mi in alpha medium supplemented with 25%
heat—inactivated horse serum (Gibco), l0 M /3-mercapto-
ethanol, 10 mi L-glutamine, 100 U/mI penicillin, 100 g!ml
streptomycin, and 7.5% pokeweed mitogen—stimulated mouse
spleen cell-conditioned medium (PWM-SCM) and made semi-
solid with 0.9% methylcellulose. The cultures were incubated
for five days as above. Granulocyte—macrophage colonies were
identified by inverted microscopy as aggregates of 40 or more
cells. Megakaryocyte colonies were identified as aggregates of
three or more cells with characteristic refractile cell membranes
and translucent agranular cytoplasm. In preliminary experi-
ments, cytochemical staining of the cultures in situ for the
megakaryocyte—specific enzyme acetylcholinesterase [201 con-
firmed the accuracy of scoring these colonies by morphology
alone.
Under these culture conditions, l0 murine marrow cells gave
rise to 227 54 (mean SEM) CFU-E—, 25 2 BFU-E.,
101 8 CFU-GM—, and 22 2 CFU-Meg—derived colonies
(N = 7). No erythroid colonies formed in the absence of Ep.
Human colony—forming assays
For most experiments, CFU-E— and BFU-E—derived colo-
nies were grown in methylcellulose as described above except
the cells were cultured for seven and 14 days, respectively, and
PHA-stimulated peripheral blood leukocyte—conditioned me-
dium (PHA-LCM) was substituted for PHA-LBRM. In certain
experiments, erythroid colonies were grown in plasma clot and
identified by benzidine staining. Granulocyte—macrophage and
megakaryocyte colonies were grown in methylcellulose as
previously described [15]. PHA-LCM was used as a source of
erythroid burst—promoting activity (at a concentration in cul-
ture of 2%) and granulocyte—macrophage and megakaryocyte
CSA (at a concentration of 2.5%). Under these culture condi-
tions, i05 human marrow cells gave rise to 95 25 CFU-E—,
71 11 BFU-E-, 106 19 CFU-GM-, and 12 3 CFU-
Meg—derived colonies (N = 5). No erythroid colonies devel-
oped in the absence of Ep.
Erythropoietin
The Ep used in these studies was partially purified from the
urine of a patient with pure red cell aplasia by a four—step
procedure which included ion exchange and concanavalin-A
affinity chromatograpy [16]. The final preparation had an activ-
ity of approximately 500 units/mg protein.
Spermine and spermidine
The free base forms of spermine and spermidine (purity 
98%; Sigma) were dissolved in phosphate—buffered saline and
added to culture at various concentrations between 5 X i07 M
and 1 X 10 M.
Data analysis
The results expressed as "percent control" in Figures 1
through 3 have been normalized to colony growth in the
absence of added spermine or spermidine.
Results
Spermine in concentrations> 10-6 M caused a non-specific,
dose—dependent inhibition of erythroid and non-erythroid col-
ony growth from murine and human marrow cells (Fig. 1),
Half—maximal and maximal inhibition were observed at concen-
trations of 2 to 5 x 10_6 M and 2 X io M, respectively.
Spermidine in concentrations > 1 to 2 x lO_6 M also non-
specifically inhibited colony formation by murine and human
marrow cells (Fig. 2). Half—maximal and maximal inhibition of
murine colony growth were seen at 5 x 10-6 — 1 X l0 M and
5 X i0 M, respectively. The corresponding values for human
colony growth were 1 to 1.5 x i0 M and 5 x l0 M,
respectively. Neither CFU-E— nor BFU-E—derived colony
growth showed greater sensitivity to the inhibitory activity of
spermine or spermidine than granulocyte—macrophage or mega-
karyocyte colony growth.
Additional studies were performed to determine whether
spermine— and spermidine—induced inhibition of erythroid and
non-erythroid colony growth could be overcome by increasing
concentrations of Ep or a source of CSA. Murine or human
cells were cultured in the piesence or absence of partially
inhibitory concentrations of spermine or spermidine. Although
Ep stimulated a dose—dependent increase in erythroid colony
growth in the presence of either polyamine, Ep concentrations
up to 5 units/mI failed to restore CFU-E— or BFU-E—derived
colony growth to levels observed in the absence of added
spermine or spermidine (Fig. 3). Spermine and spermidine
completely abolished the dose—dependent stimulation of murine
and human granulocyte—macrophage and megakaryocyte col-
ony growth by increasing concentrations of CSA (Fig. 4).
In order for erythroid colonies to be recognizable in methyl-
cellulose culture, they must be visibly hemoglobinized. Hence,
spuriously low colony counts conceivably could result if
spermine or spermidine inhibited the in vitro hemoglobinization
of colonial erythroblasts. To examine this possibility, duplicate




Fig. 1. The effect of various concentrations of spermine on hematopoi-
etic colony growth by (A) mouse and (B) human marrow cells. The data
have been normalized to colony growth in the absence of spermine.
Each point represents the mean SEM of four separate experiments.
Symbols are: (•—I) CFU-E; (O---O) BFU-E; (A—A) CFU-GM;
(A A) CFU-MEG.
culture. Erythroid colony numbers in plasma clot, as deter-
mined by benzidine staining, were equivalent to colony num-
bers in methylcellulose. Dose—response relationships for
spermine and spermidine obtained in plasma clot cultures were
identical to those obtained in methylcellulose (data not shown).
Discussion
The polyamines are a family of organic cations which are
involved in the regulation of cellular proliferation and differen-
tiation. Serum levels of the polyamines are elevated in the
setting of CRF and are lowered acutely by hemodialysis [21].
Several workers have proposed that the polyamines may be
important in the pathogenesis of several types of organ dysfunc-
tion associated with CRF [10, 22, 23]. In particular, Radtke et al
have suggested that spermine may play a role in the develop-









Fig. 2. The effect of various concentrations of spermidine on hemato-
poietic colony growth by (A) mouse and (B) human marrow cells. The
data and symbols are presented as described for Figure 1. Each point
represents the mean SEM of four separate experiments.
that spermine and spermidine inhibit, in a dose—dependent
fashion, erythroid colony growth from mouse fetal liver and
human marrow cells. Moreover, they observed the erythro-
poietic inhibitor in uremic serum to be of the same relative
molecular weight as spermine on gel filtration. Finally, a rabbit
anti-spermine antiserum neutralized the inhibitory activity in
uremic serum. Notably absent from that report were studies to
evaluate the specificity of the inhibition.
We have used a panel of mouse and human colony—forming
assays to examine the effects of spermine and spermidine on in
vitro hematopoiesis. We have confirmed the observations of
Radtke et al that spermine and spermidine inhibit erythroid
colony growth. However, the inhibitory activity was non-
specific. Granulocyte—macrophage and megakaryocyte colony
growth were just as sensitive to the inhibitory effects of the two
polyamines as erythroid colony growth (Figs. 1 and 2). Further-
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Fig. 4. The effect of increasing CSA on granulocyte—macrophage and
megakaryocyte colony growth from (A) mouse and (B) human marrow
cells cultured in the presence or absence of partially inhibitory concen-
trations of spermine or spermidine. The data have been normalized to
colony growth at 7.5% PWM-SCM and 2.5% PHA-LCM without
spermine or spermidine. Symbols are: (A— .—A) CFU-GM;(A. . A) CFU-MEG.
about 1 X i0 M [211. Thus, Radtke et a! found inhibition of
colony growth at polyamine concentrations observed in vivo
whereas Caro and Erslev and this study did not.
Fetal calf serum contains an enzyme, polyamine oxidase
(PAO), which oxidizes spermine and spermidine to their corre-
sponding aminoaldehydes [26—281. These aminoaldehydes
and/or their degradation products have been shown to inhibit
the proliferation of a variety of cell types in vitro [25, 29—311.
One might speculate that these toxic oxidation products could
be responsible for the non-specific inhibition we observed,
thereby masking erythroid—specific effects of the parent poly-
amines. However, this would seem unlikely since granulocyte—
macrophage and megakaryocyte colony growth in horse serum
and non-pregnant human plasma, both of which are devoid of
PAO activity [32, 33], were as sensitive to the inhibitory effects
of spermine and spermidine as was erythroid colony growth in
fetal calf serum (Fig. 1 and 2).
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Fig. 3. The effect of increasing concentrations of erythropoietin on
CFU-E— and BFU-E—derived colony growth from (A) mouse and (B)
human marrow cells cultured in the presence or absence of partially
inhibitory concentrations of spermine or spermidine. The data have
been normalized to colony growth at 1 unit erythropoietin/ml without
spermine or spermidine. Symbols are: (•—•) CFU-E; (O---O) BFU-E.
more, at partially inhibitory concentrations of spermine and
spermidine, the inhibition of erythroid and non-erythroid col-
ony growth could not be overcome by increasing concentra-
tions of Ep or sources of CSA, respectively. Similar observa-
tions for spermine have been reported in abstract form by Caro,
Hickey and Erslev [24].
The hematopoietic inhibitory activity of the two polyamines
was seen at concentrations > 10 M. Caro and Erslev, in a
recent review, also noted inhibition of murine erythroid and
granulocyte/macrophage colony growth at spermine concentra-
tions > 10-6 M [4]. Similarly, Hussain, Smith and Allen
observed inhibition of DNA synthesis by PHA-stimulated rat
thymic lymphocytes at spermine concentrations  i0M [25].
However, Radtke et a! observed inhibition of CFU-E—derived
colony growth from mouse fetal liver cells and human marrow
cells at spermine and spermidine concentrations as low as i0
to 10—8 M [10]. The explanation for these differences is not
immediately apparent but may be related, at least in part, to
differences in culture conditions. Spermine and spermidine
concentrations in uremic sera have been reported to average
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Anemia is the most common hematologic abnormality in
CRF; granulocytopenia and thrombocytopenia are not usually
seen. Thus, if inhibition of erythroid colony growth is a valid
model of the blunted erythropoietic response in CRF, the
inhibition should be lineage specific. We have recently shown
that the inhibitory activity in uremic serum is non-specific,
affecting murine erythroid and non-erythroid colony growth
equally [14]. Likewise, spermine and spermidine are non-
specific inhibitors of murine and human colony growth. Hence,
the erythropoietic inhibitory activity of these two polyamines
and of whole uremic serum, at least as defined in vitro would
appear to be of little pathophysiologic importance unless there
exist unrecognized repair mechanisms in vivo for granulopoie-
sis and thrombopoiesis. Several clinical studies suggest that
uremic inhibitors may play a role in the pathogenesis of the
anemia of CRF in some patients [4—8]. However, determination
of their significance awaits the results of therapeutic trials with
recombinant Ep and the correlation of these results with
improved in vitro assays for inhibitors which are specific for
erythropoiesis.
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